Published on 9 May 2024 on Simply Wall St. via Yahoo Finance
Analysts Are Updating Their Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Estimates After Its...
There's been a notable change in appetite for Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) shares in the week since its quarterly report, with the stock down 11% to US$42.30. The results don't look great, especially considering that statutory losses grew 19% toUS$0.54 per share. Revenues of US$172,325,000 did beat expectations by 4.9%, but it looks like a bit of a cold comfort. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.
Check out our latest analysis for Apellis Pharmaceuticals
